Stockscreener 앱 받기
1.58
1.25%
-0.02
전일 마감가:
$1.60
열려 있는:
$1.64
하루 거래량:
53,633
Relative Volume:
0.22
시가총액:
$82.92M
수익:
-
순이익/손실:
$-4.61M
주가수익비율:
-12.60
EPS:
-0.1254
순현금흐름:
$-3.10M
1주 성능:
-2.47%
1개월 성능:
-7.06%
6개월 성능:
-28.83%
1년 성능:
+13.67%
1일 변동 폭
$1.5601
$1.67
1주일 범위
$1.51
$1.73
52주 변동 폭
$1.03
$3.349
Okyo Pharma Limited Stock (OKYO) Company Profile
Compare OKYO vs VRTX, REGN, ALNY, ARGX, INSM
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
OKYO
Okyo Pharma Limited
|
1.58 | 82.92M | 0 | -4.61M | -3.10M | -0.1254 |
VRTX
Vertex Pharmaceuticals Inc
|
454.97 | 115.58B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
749.47 | 79.23B | 14.34B | 4.50B | 3.77B | 41.56 |
ALNY
Alnylam Pharmaceuticals Inc
|
328.70 | 43.59B | 3.71B | 313.75M | 465.38M | 2.2571 |
ARGX
Argen X Se Adr
|
697.05 | 43.26B | 4.16B | 1.29B | 734.26M | 19.58 |
INSM
Insmed Inc
|
148.31 | 31.97B | 606.42M | -1.28B | -997.58M | -6.403 |
Okyo Pharma Limited Stock (OKYO) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-02-20 | 개시 | Piper Sandler | Overweight |
| 2025-12-08 | 개시 | B. Riley Securities | Buy |
Okyo Pharma Limited 주식(OKYO)의 최신 뉴스
How does OKYO Pharma Limited compare to its peersGlobal Markets & Accurate Buy Signal Notifications - baoquankhu1.vn
OKYO Earnings History & Surprises | EPS & Revenue Results | OKYO PHARMA LTD (NASDAQ:OKYO) - ChartMill
OKYO Pharma director acquires additional shares on NASDAQ By Investing.com - Investing.com Australia
OKYO Pharma Chairman Increases Stake Following Positive Neuropathic Corneal Pain Trial - TipRanks
OKYO Pharma executive chairman linked entity acquires additional shares on NASDAQ - Investing.com
OKYO Pharma Announces Chairman and Founder Acquires Shares - The Manila Times
OKYO Pharma director acquires additional shares on NASDAQ - Investing.com UK
OKYO Pharma executive chairman increases stake with share purchase - Proactive Investors
OKYO Pharma (NASDAQ: OKYO) chair adds shares as NCP drug advances - Stock Titan
OKYO Pharma Director Boosts Stake as Lead Eye-Pain Drug Advances Toward Phase 2b/3 - TipRanks
OKYO Pharma Announces Director Acquires Shares - The Manila Times
OKYO Pharma (NASDAQ: OKYO) director boosts stake with 5,000-share purchase - Stock Titan
OKYO Pharma director acquires 30,980 shares, increases total holding By Investing.com - Investing.com India
OKYO Pharma announces director stock purchase - Proactive financial news
OKYO Pharma Executive Increases Stake Following Positive Urcosimod Trial Progress - TipRanks
OKYO Pharma director acquires 30,980 shares, increases total holding - Investing.com
OKYO Pharma Limited Reports Share Acquisition by Chief Development Officer and Advances in Neuropathic Corneal Pain Therapy Development - Quiver Quantitative
OKYO Pharma Announces Chief Development Officer and Director Acquires Shares - The Manila Times
Biotech executive buys more OKYO stock, lifting stake to 108,920 shares - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial By Investing.com - Investing.com India
OKYO Pharma (OKYO) Chief Development Officer reports stock and option holdings - Stock Titan
OKYO Pharma (OKYO) director Cerrone reports 10.5M common-share stake on Form 3 - Stock Titan
OKYO Pharma reports improved quality-of-life outcomes in mid-stage eye pain trial - Proactive Investors
Urcosimod Phase 2 NCP data show QoL gains, OKYO Pharma (OKYO) plans Phase 2b/3 - Stock Titan
OKYO Pharma reports quality of life improvements in pain trial - Investing.com
OKYO Pharma Reports New Phase 2 Data Demonstrating Meaningful Improvements in Patient-Reported Quality of Life Outcomes with Urcosimod in Neuropathic Corneal Pain - The Manila Times
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Short Interest Down 12.4% in February - MarketBeat
OKYO Pharma (NASDAQ:OKYO) Stock Price Up 1.2%Time to Buy? - MarketBeat
OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
OKYO Pharma prices public offering at $1.85/share to raise up to $20M - MSN
OKYO Pharma Raises About $22 Million After Underwriter Partially Exercises Share Option - The Globe and Mail
OKYO Pharma (OKYO) lifts equity proceeds to $22M after option exercise - Stock Titan
Market Wrap: Is OKYO Pharma Limited a turnaround story2026 Momentum Check & Free Safe Capital Growth Stock Tips - baoquankhu1.vn
Geopolitics Watch: Will Coeptis Therapeutics Holdings Inc. Equity Warrant benefit from rate cutsQuarterly Portfolio Report & AI Based Trade Execution Alerts - baoquankhu1.vn
Published on: 2026-03-07 08:54:47 - baoquankhu1.vn
Setup Watch: Can OKYO Pharma Limited maintain sales growthQuarterly Profit Review & Growth Focused Entry Point Reports - baoquankhu1.vn
Market Rankings: Is OKYO Pharma Limited stock trending bullishIndex Update & Capital Protection Trade Alerts - baoquankhu1.vn
OKYO Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
OKYO Abstract Selected for Presentation at Premier Global Ophthalmology Congress - The Manila Times
OKYO Pharma to present first-in-human urcosimod data at ARVO 2026 - Proactive Investors
OKYO Pharma’s Urcosimod NCP Data Selected for Presentation at ARVO 2026 - TipRanks
OKYO Pharma's Urcosimod Selected for Presentation at ARVO 2026 Annual Meeting Following Positive Phase 2a Trial Results for Neuropathic Corneal Pain Treatment - Quiver Quantitative
OKYO (Nasdaq: OKYO) to present Fast Track NCP therapy data at ARVO 2026 - Stock Titan
Analysts Set OKYO Pharma Limited Sponsored ADR (NASDAQ:OKYO) Target Price at $6.00 - Defense World
Piper Sandler Initiates Coverage on OKYO Pharma (NASDAQ:OKYO) - Defense World
OKYO Pharma (NASDAQ:OKYO) Raised to "Strong-Buy" at Piper Sandler - MarketBeat
Piper Sandler initiates OKYO Pharma stock with Overweight rating By Investing.com - Investing.com Nigeria
How OKYO Pharma Limited stock compares to industry benchmarksWeekly Trade Review & Daily Volume Surge Signals - mfd.ru
CEO Moves: Is OKYO Pharma Limited a turnaround story2025 Pullback Review & Weekly High Return Stock Forecasts - baoquankhu1.vn
Okyo Pharma Limited (OKYO) 재무 분석
매출
순이익
현금흐름
주당 순 이익
1.82%
자본화:
|
볼륨(24시간):